Member Info for B2HS2L

Htothe K used the Jesus C term in a post in that thread, and that could be the reason for deletion.

ABDX didn't get any interest on what was owed.
I don't think NCYT will get the interest either, but I do expect to see all outstanding money's repaid, after we supplied a hell of a lot of PROmate that hasn't been paid for, when the Govnt needed it most.
The supply of that assay might have cost GM his job. - Just conjecture here, but it would have been JW's call..

I may be wrong, but the whole thread has been removed HillSeeker.

...and now you voted it's too late to change your vote anyway.
So the message is must try harder with comms DA, (and JW).

In case you hadn't noticed, shareholders want to pay directors on merit.
Directors are out to fleece the shareholders, because it is so easy with this type of thinking amongst shareholders..

PharmaPI -
Are there any specific to DHSC dispute resolutions, no.
Are there any resolutions likely to assist in championing our cause in the DHSC dispute, no.
There is a resolution that provides the board with an undeserved pay rise.

No and thrice no will I be voting YES to their payrise.

1 Novacyt announce launch of 2 * PCR tests for Monkeypox, Novacyt sp = +2 p
2 Abingdon Health announce dispute closure with DHSC, Novacyt sp = +12p and climbing.

It's clear what investors are waiting for here.

Another good thing for our sales teams is that the Monkeypox assay is good for all our instruments, thus demonstrating that our previous customers just found yet another use for them.
Blow me down, how fortunate.

Is it possible to develop a LFT for this, - I guess we'll soon find out.

Hillseeker -
I first thought that the development of a Monkeypox assay might not be profitable for us.
My next thought was that, committed as we are to being first global responder, and also with a need to impress a very good customer - the WHO, we need to show we are on top of Monkeypox, with the lid remaining screwed down via the bioinformatics team activities.

I see no reason why this should not happen.
I'm not expecting this to be very profitable unless the virus is not controlled in undeveloped countries, or the virus becomes much more contagious.

'We continue to provide solutions for emerging and anticipated healthcare threats'.
Plugged into the bioinformatics teams automated equipment, we should see where any future mutations will take this disease. We can thus keep the Monkeypox virus in our rifle sites more easily and quickly than other manufacturers.

Great news, lets hope the likes of WHO like it as much.

"Ya know ya gonna neeeed a MyGo with that thar assay ya jus' bought"....

Why are you bothering.
Try some research if your really interested, but I suspect not.

Internal R&D promotion for Zak Chivers, to R&D Senior Scientist.
Expected to be innovating according to Jemma stokes

FWIW Ad, -
I think this new LFT might have been launched under the MICROGEN BIOPRODUCTS brand because it replaces a previous product that was supposed to launch last year.

2 & 3 November 2022 | NEC, Birmingham
https://www.lab-innovations.com/products/pathflowr-rapid-tests/

• PathFlow® COVID-19 Rapid Antigen Self-Test – A self-test LFT to detect SARS-CoV-2 antigens using oral fluid samples and provides results in approximately 15 minutes.

'Choose an LFT with Saliva'
It's a Saliva & Sputum test, with 93% specificity and specificity of 100 %.
The instructions ( https://twitter.com/Larry64450205/status/1540201954080702467/photo/2 ) state "Spit into the funnel after clearing your throat by coughing deeply"

From Google search:
sputum / noun
a mixture of saliva and mucus coughed up from the respiratory tract, typically as a result of infection or other disease and often examined microscopically to aid medical diagnosis.

saliva / noun
watery liquid secreted into the mouth by glands, providing lubrication for chewing and swallowing, and aiding digestion.

++++
This test replaces -
From 29.06.2021 RNS :

"PathFlow® COVID-19 Rapid Antigen is a self-test LFT to detect SARS-CoV-2 antigens using oral fluid samples and provides results in approximately 15 minutes.
This test demonstrated a sensitivity of 90.1% and specificity of 99.3% from 303 clinical samples.
The test offers mass screening for home, travel, events, and workplace markets.
Novacyt expects to make this LFT available as a CE Marked product shortly.

Update: RNS 30.09.2021 - Further to the announcement on 29 June 2021, the Company's confirms there is a delay in the launch of PathFlow® COVID-19 Rapid Antigen, a self-LFT to detect SARS-CoV-2 antigens, previously expected in Q3 2021.
This delay is due to increased demand for self-test approvals causing a backlog of tests currently under review by the Company's Notified Body.

PathFlow® COVID-19 Rapid Antigen Pro and PathFlow® COVID-19 Rapid Antigen have been developed with a partner through an OEM agreement in conjunction with Novacyt's Microgen Bioproducts division."

+++++
Novacyt don't manufacture LFT's, so assume development partner still involved, but is it the same partner?

++++
Sensitivity of "PathFlow® COVID-19 Rapid Antigen = 90.1%
Specificity of ditto = 99.3%

Sensitivity of new test = 93.0%
Specificity of ditto = 100%

Think you might find help with that difficult to come by on this board.
We're not interested in digging that up again as it was discussed to death the first, second and third time around.
You didn't miss much, sorry.

https://www.linkedin.com/posts/simon-cook-60a12742_mygo-novacyt-leadingtheway-activity-6869215329705328641-ZMTl/

Note Natasha Maximchuk, Sales Manager at IT-IS, offering limited time MyGo black Friday deal last November. In December, posters spotted TATA using the MyGo Pro to process their own assay.

It's possible another deal is being planned, hence the timescale.

This link chosen because there appears to be a problem displaying Natasha Maximchuk's pages on LinkedIn.

Perhaps a limited time period for product offers?

johnny - My meaning was that there has been zero effort so far to attract II's.
This situation should now change the board's perspective, up to them how they do the attracting.
Goodness knows that James Wakefield should know a trick or two on this subject!

Poidster -
"Paul Jackson Pollock was an American painter and a major figure in the abstract expressionist movement. He was widely noticed for his "drip technique" of pouring or splashing liquid household paint onto a horizontal surface, enabling him to view and paint his canvases from all angles." Wikipedia

Are you going to have an open day when your satisfied it's done?

Perhaps we could convene a makeshift AGM on your patio,
where we can tell them where to shove the payrise resolution.
Better still we will delete that resolution!

Stay well Poidster, silence is golden at present.

This will teach them to go get some II's now..